» Articles » PMID: 22178192

Site-specific Oxidation of Apolipoprotein A-I Impairs Cholesterol Export by ABCA1, a Key Cardioprotective Function of HDL

Overview
Specialties Biochemistry
Biophysics
Date 2011 Dec 20
PMID 22178192
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

The mechanisms that deprive HDL of its cardioprotective properties are poorly understood. One potential pathway involves oxidative damage of HDL proteins by myeloperoxidase (MPO) a heme enzyme secreted by human artery wall macrophages. Mass spectrometric analysis demonstrated that levels of 3-chlorotyrosine and 3-nitrotyrosine - two characteristic products of MPO - are elevated in HDL isolated from patients with established cardiovascular disease. When apolipoprotein A-I (apoA-I), the major HDL protein, is oxidized by MPO, its ability to promote cellular cholesterol efflux by the membrane-associated ATP-binding cassette transporter A1 (ABCA1) pathway is diminished. Biochemical studies revealed that oxidation of specific tyrosine and methionine residues in apoA-I contributes to this loss of ABCA1 activity. Another potential mechanism for generating dysfunctional HDL involves covalent modification of apoA-I by reactive carbonyls, which have been implicated in atherogenesis and diabetic vascular disease. Indeed, modification of apoA-I by malondialdehyde (MDA) or acrolein also markedly impaired the lipoprotein's ability to promote cellular cholesterol efflux by the ABCA1 pathway. Tandem mass spectrometric analyses revealed that these reactive carbonyls target specific Lys residues in the C-terminus of apoA-I. Importantly, immunochemical analyses showed that levels of MDA-protein adducts are elevated in HDL isolated from human atherosclerotic lesions. Also, apoA-I co-localized with acrolein adducts in such lesions. Thus, lipid peroxidation products might specifically modify HDL in vivo. Our observations support the hypotheses that MPO and reactive carbonyls might generate dysfunctional HDL in humans. This article is part of a Special Issue entitled Advances in High Density Lipoprotein Formation and Metabolism: A Tribute to John F. Oram (1945-2010).

Citing Articles

Radical Oxygen Species, Oxidized Low-Density Lipoproteins, and Lectin-like Oxidized Low-Density Lipoprotein Receptor 1: A Vicious Circle in Atherosclerotic Process.

Munno M, Mallia A, Greco A, Modafferi G, Banfi C, Eligini S Antioxidants (Basel). 2024; 13(5).

PMID: 38790688 PMC: 11118168. DOI: 10.3390/antiox13050583.


Short-chain fatty acids in nonalcoholic fatty liver disease: New prospects for short-chain fatty acids as therapeutic targets.

Li X, He M, Yi X, Lu X, Zhu M, Xue M Heliyon. 2024; 10(5):e26991.

PMID: 38486722 PMC: 10937592. DOI: 10.1016/j.heliyon.2024.e26991.


The Oxidized Lipoproteins In Vivo: Its Diversity and Behavior in the Human Circulation.

Itabe H, Obama T Int J Mol Sci. 2023; 24(6).

PMID: 36982815 PMC: 10053446. DOI: 10.3390/ijms24065747.


Isoform-specific modification of apolipoprotein E by 4-hydroxynonenal: protective role of apolipoprotein E3 against oxidative species.

Abeer M, Abdulhasan A, Haguar Z, Narayanaswami V FEBS J. 2023; 290(11):3006-3025.

PMID: 36661393 PMC: 11296219. DOI: 10.1111/febs.16729.


Associations between myeloperoxidase and paraoxonase-1 and type 2 diabetes in patients with ischemic heart disease.

Nessler K, Grzybczak R, Nessler M, Zalewski J, Gajos G, Windak A BMC Cardiovasc Disord. 2022; 22(1):521.

PMID: 36463116 PMC: 9719221. DOI: 10.1186/s12872-022-02928-8.


References
1.
Lowenstein C, Cameron S . High-density lipoprotein metabolism and endothelial function. Curr Opin Endocrinol Diabetes Obes. 2010; 17(2):166-70. DOI: 10.1097/MED.0b013e32833727ee. View

2.
Bowry V, Stanley K, Stocker R . High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci U S A. 1992; 89(21):10316-20. PMC: 50329. DOI: 10.1073/pnas.89.21.10316. View

3.
Klebanoff S . Oxygen metabolism and the toxic properties of phagocytes. Ann Intern Med. 1980; 93(3):480-9. DOI: 10.7326/0003-4819-93-3-480. View

4.
Getz G, Wool G, Reardon C . Biological properties of apolipoprotein a-I mimetic peptides. Curr Atheroscler Rep. 2010; 12(2):96-104. PMC: 3087815. DOI: 10.1007/s11883-010-0097-4. View

5.
Shao B, Heinecke J . Using tandem mass spectrometry to quantify site-specific chlorination and nitration of proteins: model system studies with high-density lipoprotein oxidized by myeloperoxidase. Methods Enzymol. 2008; 440:33-63. DOI: 10.1016/S0076-6879(07)00803-8. View